12:00 AM
 | 
Dec 14, 2009
 |  BC Week In Review  |  Company News  |  Deals

Seattle Genetics, Roche deal

Seattle Genetics said Roche's Genentech Inc. unit will end a 2007 deal and return to Seattle Genetics all rights to dacetuzumab (SGN-40). The mAb targeting CD40 is in four Phase Ib trials to treat relapsed or refractory non-Hodgkin's lymphoma and multiple...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >